T1D PT101
Alternative Names: T1D-PT101Latest Information Update: 10 Mar 2024
At a glance
- Originator Porosome Therapeutics
- Class Antihyperglycaemics
- Mechanism of Action Insulin secretion stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Type 1 diabetes mellitus
Most Recent Events
- 27 Feb 2024 Preclinical trials in Type 1 diabetes mellitus in USA (unspecified route)